manufacturers of glp 1 drugs Asia-Pacific Glucagon-like Peptide-1 (GLP-1) Agonists Companies Medicare to start covering GLP-1

Figure 1 Table 1 Effects of GIP receptor agonism or antagonism on glycemic control, body weight, and energy balance in animal models of obesity and diabetes (modified according to Campbell and Nauck) (47, 49)

The lower intestine produces potent amounts of natural GLP after a meal

Flint A, Raben A, Blundell JE, Astrup A

Looking ahead, further research should aim to define the most effective combinations of pharmacotherapy and lifestyle interventions, with a focus on preserving lean mass and sustaining long-term metabolic health

When switching from Mounjaro to retatrutide does become possible, the transition will likely follow established principles for transitioning between GLP-1 medications

MAN has participated on advisory boards or has been invited as a speaker by Amylin Pharmaceuticals, AstraZeneca, Berlin Chemie, Boehringer Ingelheim, Bristol-Myers Squibb, Diartis Pharmaceuticals Inc., Eli Lilly & Co., GlaxoSmithKline, Hoffmann-La Roche Ltd., Intarcia Therapeutics Inc., Janssen Global Services, MannKind Corp., MSD, Novo Nordisk, Novartis, Sanofi, Takeda, Versartis and Wyeth Research